Evaluation of Naloxone Co-Prescribing Rates for Older Adults Receiving Opioids via a Meds-to-Beds Program

References

• Hedegaard H, Bastian BA, Trinidad JP, Spencer M, Warner M. Drugs most frequently involved in drug overdose deaths: United States, 2011–2016. Journal Issue. Hyattsville, MD 2018. Contract No.: 9.
   Google Scholar
• Opioids: commonly used terms [Internet]. Atlanta, GA: Centers for Disease Control and Prevention; 2021. Available from: https://www.cdc.gov/opioids/basics/terms.html.
   Google Scholar
• McCormick CD, Dadiomov D, Trotzky-Sirr R, Qato DM. Prevalence and distribution of high-risk prescription opioid use in the United States, 2011-2016. Pharmacoepidemiol Drug Saf. 2021;30(11):1532–40. doi:10.1002/pds.5349.
   PubMed Web of Science ®Google Scholar
• Martin CM, Forrester CS. Anticipating and managing opioid side effects in the elderly. Consult Pharm. 2013;28(3):150–9. doi:10.4140/TCP.n.2013.150.
   PubMedGoogle Scholar
• Mason M, Soliman R, Kim HS, Post LA. Disparities by sex and race and ethnicity in death rates due to opioid overdose among adults 55 years or older, 1999 to 2019. JAMA Netw Open. 2022;5(1):e2142982. doi:10.1001/jamanetworkopen.2021.42982.
   PubMed Web of Science ®Google Scholar
• Narcan Nasal Spray (naloxone hydrochloride) [package insert]. Plymouth Meeting, PA: Emergent Devices Inc; November 2020.
   Google Scholar
• Barton ED, Ramos J, Colwell C, Benson J, Baily J, Dunn W. Intranasal administration of naloxone by paramedics. Prehosp Emerg Care. 2002;6(1):54–8. doi:10.1080/10903120290938797.
   PubMedGoogle Scholar
• U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Narcan NDA 016636 approval letter, April 13, 1971.
   Google Scholar
• Roberts AW, Carpenter DM, Smith A, Look KA. Reviewing state-mandated training requirements for naloxone-dispensing pharmacists. Res Social Adm Pharm. 2019;15(2):222–5. doi:10.1016/j.sapharm.2018.04.002.
   PubMed Web of Science ®Google Scholar
• Winhusen T, Wilder C, Lyons MS, Theobald J, Kropp F, Lewis D. Evaluation of a personally-tailored opioid overdose prevention education and naloxone distribution intervention to promote harm reduction and treatment readiness in individuals actively using illicit opioids. Drug Alcohol Depend. 2020;216:108265. doi:10.1016/j.drugalcdep.2020.108265.
   PubMed Web of Science ®Google Scholar
• Strand MA, Eukel H, Frenzel O, Skoy E, Steig J, Werremeyer A. Program evaluation of the Opioid and Naloxone Education (ONE Rx) program using the RE-AIM model. Res Social Adm Pharm. 2020;16(9):1248–54. doi:10.1016/j.sapharm.2019.11.016.
   PubMed Web of Science ®Google Scholar
• Oliva EM, Christopher MLD, Wells D, Bounthavong M, Harvey M, Himstreet J, Emmendorfer T, Valentino M, Franchi M, Goodman F, et al. Opioid overdose education and naloxone distribution: development of the Veterans Health Administration’s national program. J Am Pharm Assoc (2003). 2017;57(2S):S168–S79 e4. doi:10.1016/j.japh.2017.01.022.
   PubMed Web of Science ®Google Scholar
• Zedler BK, Saunders WB, Joyce AR, Vick CC, Murrelle EL. Validation of a screening risk index for serious prescription opioid-induced respiratory depression or overdose in a US commercial health plan claims database. Pain Med. 2018;19(1):68–78. doi:10.1093/pm/pnx009.
   PubMed Web of Science ®Google Scholar
• Clinical Resource, Naloxone for Opioid Overdose. Pharmacist’s Letter/Prescriber’s Letter. September 2020.
   Google Scholar
• Prescribe to Prevent. Instructions for healthcare professionals: prescribing naloxone [Internet]. 2012. Available from: http://www.prescribetoprevent.org/wp-content/uploads/2012/11/one-pager_12.pdf.
   Google Scholar
• Food and Drug Administration. FDA Requiring Labeling Changes for Opioid Pain Medicines, Opioid Use Disorder Medicines Regarding Naloxone [Internet]. Food and Drug Administration; 2020. Available from: https://www.fda.gov/news-events/press-announcements/fda-requiring-labeling-changes-opioid-pain-medicines-opioid-use-disorder-medicines-regarding.
   Google Scholar
• Pammett R. Naloxone for opioid overdose - virtual Q&A [Internet]. Canadian Pharmacists Association; 2022. Available from: https://www.pharmacists.ca/cpha-ca/assets/File/education-practice-resources/NaloxoneWebinarQA_Sept22.pdf.
   Google Scholar
• American Medical Association Opioid Task Force. Help save lives: co-prescribe naloxone to patients at risk of overdose: American Medical Association; 2017. Available from: https://www.end-opioid-epidemic.org/wp-content/uploads/2017/08/AMA-Opioid-Task-Force-naloxone-one-pager-updated-August-2017-FINAL.pdf.
   Google Scholar
• Stein BD, Smart R, Jones CM, Sheng F, Powell D, Sorbero M. Individual and community factors associated with naloxone co-prescribing among long-term opioid patients: a retrospective analysis. J Gen Intern Med. 2021;36(10):2952–7. doi:10.1007/s11606-020-06577-5.
   PubMed Web of Science ®Google Scholar
• Lahidji S, Oliva E, Jarzebowski M, Mudumbai SC, Lake T, Krishnamoorthy V, Raghunathan K, Bryan WE.3rd. Naloxone dispensing in patients at risk for opioid overdose after total knee arthroplasty within the Veterans Health Administration. Fed Pract. 2022;39(2):64–9. doi:10.12788/fp.0227.
   PubMedGoogle Scholar
• Jones CM, Compton W, Vythilingam M, Giroir B. Naloxone co-prescribing to patients receiving prescription opioids in the Medicare part D program, United States, 2016-2017. JAMA. 2019;322(5):462–4. doi:10.1001/jama.2019.7988.
   PubMed Web of Science ®Google Scholar
• Darracq MA, Lee J, Wilson T, Lasoff D, Armenian P. Pharmacist dispensed naloxone: knowledge, availability, participation and cost in selected California counties. Int J Drug Policy. 2019;71:113–7. doi:10.1016/j.drugpo.2019.06.001.
   PubMed Web of Science ®Google Scholar
• Patel A, Dodd MA, D’Angio R, Hellinga R, Ahmed A, Vanderwoude M, Sarangarm P. Impact of discharge medication bedside delivery service on hospital reutilization. Am J Health Syst Pharm. 2019;76(23):1951–7. doi:10.1093/ajhp/zxz197.
   PubMed Web of Science ®Google Scholar
• Zillich AJ, Jaynes HA, Davis HB, Lantaff WM, Myers J, Perkins SM, Shan M, Snyder ME. Evaluation of a “Meds‐to‐Beds” program on 30‐day hospital readmissions. J Am Coll Clin Pharm. 2020;3(3):577–85. doi:10.1002/jac5.1183.
   Google Scholar
• Lash DB, Mack A, Jolliff J, Plunkett J, Joson JL. Meds‐to‐Beds: the impact of a bedside medication delivery program on 30‐day readmissions. J Am Coll Clin Pharm. 2019;2(6):674–80. doi:10.1002/jac5.1108.
   Google Scholar
• King PK, Burkhardt C, Rafferty A, Wooster J, Walkerly A, Thurber K, Took R, Masterson J, St. Peter WL, Furuno JP, et al. Quality measures of clinical pharmacy services during transitions of care. J Am Coll Clin Pharm. 2021;4(7):883–907. doi:10.1002/jac5.1479.
   Google Scholar
• Foster L, Choxi S, Rosenberg RE, Tracy J, Toscano D, Betancur Paez J, Glick AF. Meds to beds: a quality improvement approach to optimizing the discharge medication process for pediatric patients. Jt Comm J Qual Patient Saf. 2022;48(2):92–100. doi:10.1016/j.jcjq.2021.09.014.
   PubMed Web of Science ®Google Scholar
• Findlater CK, Gerges S, Litynsky J, Robson K. Implementation of a meds to beds medication use program and parent experience at the time of transition from a neonatal intensive care unit to home. J Pediatr Pharmacol Ther. 2022;27(4):300–5. doi:10.5863/1551-6776-27.4.300.
   PubMedGoogle Scholar
• Gupta S, Winckler B, Lopez MA, Costilla M, McCarthy J, Wagner J, Broderick A, French K, Le B, Lo HY. A quality improvement initiative to improve postdischarge antimicrobial adherence. Pediatrics. 2021;147(1):e20192413. doi:10.1542/peds.2019-2413.
   PubMed Web of Science ®Google Scholar
• Samuels EA, Dwyer K, Mello MJ, Baird J, Kellogg AR, Bernstein E. Emergency department-based opioid harm reduction: moving physicians from willing to doing. Acad Emerg Med. 2016;23(4):455–65. doi:10.1111/acem.12910.
   PubMed Web of Science ®Google Scholar
• Gruver BR, Jiroutek MR, Kelly KE. Naloxone coprescription in U.S. ambulatory care centers and emergency departments. J Am Pharm Assoc (2003). 2020;60(5):e44–e9. doi:10.1016/j.japh.2020.03.009.
   PubMed Web of Science ®Google Scholar
• Jones V, Zelnicek T, Hines MT, Johnson EJ, O’Neal KS, Draugalis JR. Creation and implementation of a pharmacy-led meds-to-beds program at a large teaching hospital. J Am Pharm Assoc (2003). 2022;62(3):870–6. doi:10.1016/j.japh.2021.11.020.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71.
   PubMed Web of Science ®Google Scholar
• United States Department of Agriculture. 2010. Rural-Urban Commuting Area (RUCA) Codes [Internet]. Washington, D.C. 2020. Available from: https://www.ers.usda.gov/data-products/rural-urban-commuting-area-codes/documentation/.
   Google Scholar
• Santo L, Okeyode T, National Ambulatory Medical Care Survey: 2018. National Summary Tables.; https://www.cdc.gov/nchs/data/hus/2019/039-508.pdf.
   Google Scholar
• Naloxone prescribing and dispensing. Oklahoma State Board of Pharmacy e-Newsletter. October 2018.
   Google Scholar
• Public Health and Safety, Stat. 63 1 Nov 2014, 2021.
   Google Scholar
• Pharmacy, Stat. 59 14 Sept 2018, 2021.
   Google Scholar
• Ancker JS, Gossey JT, Nosal S, Xu C, Banerjee S, Wang Y, Veras Y, Mitchell H, Bao Y. Effect of an electronic health record “nudge” on opioid prescribing and electronic health record keystrokes in ambulatory care. J Gen Intern Med. 2021;36(2):430–7. doi:10.1007/s11606-020-06276-1.
   PubMed Web of Science ®Google Scholar